A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors.

Trial Profile

A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2014

At a glance

  • Drugs Figitumumab (Primary)
  • Indications Ewing's sarcoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Apr 2013 Planned number of patients changed from 130 to 138 as reported by German Clinical Trials Register.
    • 15 Oct 2012 Planned End Date changed from 1 Sep 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
    • 15 Oct 2012 This trial has been completed in Germany, Spain and Italy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top